1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Basal Ganglia Diseases in 8 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lagrue, E | 1 |
| Abert, B | 1 |
| Nadal, L | 1 |
| Tabone, L | 1 |
| Bodard, S | 1 |
| Medja, F | 1 |
| Lombes, A | 1 |
| Chalon, S | 1 |
| Castelnau, P | 1 |
| Hodgson, RA | 1 |
| Bedard, PJ | 1 |
| Varty, GB | 1 |
| Kazdoba, TM | 1 |
| Di Paolo, T | 1 |
| Grzelak, ME | 1 |
| Pond, AJ | 1 |
| Hadjtahar, A | 1 |
| Belanger, N | 1 |
| Gregoire, L | 1 |
| Dare, A | 1 |
| Neustadt, BR | 1 |
| Stamford, AW | 1 |
| Hunter, JC | 1 |
| Battaglia, G | 1 |
| Farrace, MG | 1 |
| Mastroberardino, PG | 1 |
| Viti, I | 1 |
| Fimia, GM | 1 |
| Van Beeumen, J | 1 |
| Devreese, B | 1 |
| Melino, G | 1 |
| Molinaro, G | 1 |
| Busceti, CL | 1 |
| Biagioni, F | 1 |
| Nicoletti, F | 1 |
| Piacentini, M | 1 |
| Meltzer, LT | 1 |
| Christoffersen, CL | 1 |
| Corbin, AE | 1 |
| Ninteman, FW | 1 |
| Serpa, KA | 1 |
| Wiley, JN | 1 |
| Wise, LD | 1 |
| Heffner, TG | 1 |
| DeLong, MR | 1 |
| Johannessen, JN | 1 |
| Sheng, JG | 1 |
| Xu, DL | 1 |
| Yu, HZ | 1 |
| Xu, XR | 1 |
| Tang, QM | 1 |
| Barbeau, A | 1 |
| Roy, M | 1 |
| Langston, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TMS Measures in Parkinson's Disease[NCT00023062] | 80 participants | Observational | 2001-08-31 | Completed | |||
| Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.[NCT00228371] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to insufficent enrolement) | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Deep Brain Stimulation Surgery for Movement Disorders[NCT01581580] | 200 participants (Anticipated) | Interventional | 2011-08-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Basal Ganglia Di | 1991 |
6 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Basal Ganglia Diseases
| Article | Year |
|---|---|
MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Basal Ganglia Diseases; Diseas | 2009 |
Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Analysis of Varianc | 2010 |
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Basal Ganglia Disease | 2007 |
CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Apomorphine; Autorecept | 1995 |
Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia | 1987 |
Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Basal Ganglia Diseases; Humans; Occupational Diseases; | 1985 |